Biogen: Reversal Of Collateral Estoppel Ruling Controls New Appeal
Mealey's (February 24, 2021, 2:09 PM EST) -- WASHINGTON, D.C. — The maker of the multiple sclerosis (MS) drug Tecfidera in a Feb. 22 appellant brief argues that before deciding whether a federal judge in Delaware erred when ruling...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login